BACKGROUND: 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors, commonly known as statins, account for the great majority of cholesterol-lowering drug use in the United States. Long-duration statin use was associated with substantially reduced risk of advanced prostate cancer in a recent large prospective study. METHODS: We examined the association between use of cholesterol-lowering drugs and prostate cancer incidence by disease stage and grade among 55,454 men in the Cancer Prevention Study II Nutrition Cohort. Proportional hazards modeling was used to calculate RRs. RESULTS: During follow-up from 1997 to 2003, we identified 3,413 cases of incident prostate cancer, including 317 cases of advanced prostate cancer. After adjustment for age, history of prostate-specific antigen testing, and other potential prostate cancer risk factors, current use of cholesterol-lowering drugs for 5 or more years was not associated with overall prostate cancer incidence (multivariate adjusted rate ratio, 1.06; 95% confidence interval, 0.93-1.20), but was associated with a marginally statistically significant reduction in risk of advanced prostate cancer (rate ratio, 0.60; 95% confidence interval, 0.36-1.00). CONCLUSION: These results provide some support for the hypothesis that long-term statin use is associated with reduced risk of advanced prostate cancer.
BACKGROUND:3-Hydroxy-3-methylglutaryl CoA reductase inhibitors, commonly known as statins, account for the great majority of cholesterol-lowering drug use in the United States. Long-duration statin use was associated with substantially reduced risk of advanced prostate cancer in a recent large prospective study. METHODS: We examined the association between use of cholesterol-lowering drugs and prostate cancer incidence by disease stage and grade among 55,454 men in the Cancer Prevention Study II Nutrition Cohort. Proportional hazards modeling was used to calculate RRs. RESULTS: During follow-up from 1997 to 2003, we identified 3,413 cases of incident prostate cancer, including 317 cases of advanced prostate cancer. After adjustment for age, history of prostate-specific antigen testing, and other potential prostate cancer risk factors, current use of cholesterol-lowering drugs for 5 or more years was not associated with overall prostate cancer incidence (multivariate adjusted rate ratio, 1.06; 95% confidence interval, 0.93-1.20), but was associated with a marginally statistically significant reduction in risk of advanced prostate cancer (rate ratio, 0.60; 95% confidence interval, 0.36-1.00). CONCLUSION: These results provide some support for the hypothesis that long-term statin use is associated with reduced risk of advanced prostate cancer.
Authors: Marian L Neuhouser; Cathee Till; Alan Kristal; Phyllis Goodman; Ashraful Hoque; Elizabeth A Platz; Ann W Hsing; Demetrius Albanes; Howard L Parnes; Michael Pollak Journal: Cancer Prev Res (Phila) Date: 2010-02-23
Authors: Wildon R Farwell; Leonard W D'Avolio; Richard E Scranton; Elizabeth V Lawler; J Michael Gaziano Journal: J Natl Cancer Inst Date: 2011-04-15 Impact factor: 13.506
Authors: Ilir Agalliu; Claudia A Salinas; Philip D Hansten; Elaine A Ostrander; Janet L Stanford Journal: Am J Epidemiol Date: 2008-06-12 Impact factor: 4.897
Authors: Huarong Huang; Xiao-Xing Cui; Shaohua Chen; Susan Goodin; Yue Liu; Yan He; Dongli Li; Hong Wang; Jeremiah Van Doren; Robert S Dipaola; Allan H Conney; Xi Zheng Journal: Anticancer Res Date: 2014-07 Impact factor: 2.480
Authors: Elizabeth A Platz; Cathee Till; Phyllis J Goodman; Howard L Parnes; William D Figg; Demetrius Albanes; Marian L Neuhouser; Eric A Klein; Ian M Thompson; Alan R Kristal Journal: Cancer Epidemiol Biomarkers Prev Date: 2009-11-03 Impact factor: 4.254
Authors: Rodney H Breau; R Jeffrey Karnes; Debra J Jacobson; Michaela E McGree; Steven J Jacobsen; Ajay Nehra; Michael M Lieber; Jennifer L St Sauver Journal: J Urol Date: 2010-06-17 Impact factor: 7.450
Authors: Keith R Solomon; Kristine Pelton; Kelly Boucher; Jinsoo Joo; Christopher Tully; David Zurakowski; Carl P Schaffner; Jayoung Kim; Michael R Freeman Journal: Am J Pathol Date: 2009-01-29 Impact factor: 4.307
Authors: Elin Thysell; Izabella Surowiec; Emma Hörnberg; Sead Crnalic; Anders Widmark; Annika I Johansson; Pär Stattin; Anders Bergh; Thomas Moritz; Henrik Antti; Pernilla Wikström Journal: PLoS One Date: 2010-12-03 Impact factor: 3.240